Epigral Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St

May 08, 2025

Epigral (NSE:EPIGRAL) Full Year 2025 Results

Key Financial Results

Revenue: ₹25.7b (up 33% from FY 2024).
Net income: ₹3.58b (up 83% from FY 2024).
Profit margin: 14% (up from 10% in FY 2024). The increase in margin was driven by higher revenue.
EPS: ₹84.68 (up from ₹47.14 in FY 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

earnings-and-revenue-growth — NSEI:EPIGRAL Earnings and Revenue Growth May 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Epigral EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 3.8%.

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India.

Performance of the Indian Chemicals industry.

The company's shares are up 3.5% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Epigral's balance sheet.

Valuation is complex, but we're here to simplify it.

Discover if Epigral might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.